CN103751792B - Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer - Google Patents
Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer Download PDFInfo
- Publication number
- CN103751792B CN103751792B CN201410017214.XA CN201410017214A CN103751792B CN 103751792 B CN103751792 B CN 103751792B CN 201410017214 A CN201410017214 A CN 201410017214A CN 103751792 B CN103751792 B CN 103751792B
- Authority
- CN
- China
- Prior art keywords
- angelicae sinensis
- radix angelicae
- intestinal
- medicine
- sinensis extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000009188 angelicae sinensis extract Substances 0.000 title claims abstract description 36
- 230000031891 intestinal absorption Effects 0.000 title claims abstract description 26
- 239000003623 enhancer Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 71
- 238000010521 absorption reaction Methods 0.000 claims abstract description 46
- 229940079593 drug Drugs 0.000 claims abstract description 25
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 43
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 43
- 235000001785 ferulic acid Nutrition 0.000 claims description 28
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 27
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 27
- 229940114124 ferulic acid Drugs 0.000 claims description 27
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 27
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 27
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 15
- 230000002183 duodenal effect Effects 0.000 claims description 10
- 210000001198 duodenum Anatomy 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 6
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 210000001630 jejunum Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000003405 ileum Anatomy 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940042126 oral powder Drugs 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 230000002079 cooperative effect Effects 0.000 abstract description 3
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 61
- 230000010412 perfusion Effects 0.000 description 17
- 239000009636 Huang Qi Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 210000004911 serous fluid Anatomy 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 101100011900 Drosophila melanogaster rl gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HZYCAKGEXXKCDM-UHFFFAOYSA-N Methyl 2-(methylthio)acetate Chemical compound COC(=O)CSC HZYCAKGEXXKCDM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 fatty acid salt Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medical art, disclose the application of Radix Angelicae Sinensis extract as natural intestinal absorption enhancer.The present invention, using Radix Angelicae Sinensis extract as natural intestinal absorption enhancer, can use with being promoted compatibility of drugs or making composite drug, can play significant cooperative effect, improves the bioavailability being promoted medicine, and can not cause damage to the mucosa of absorption site.Radix Angelicae Sinensis extract is applied as natural intestinal absorption enhancer and has major application value.
Description
Technical field
The present invention relates to medical art, more specifically, relate to the application of Radix Angelicae Sinensis extract as natural intestinal absorption enhancer.
Background technology
Research finds, in the research of medicine, is eliminated or needs to be improved by preparation means to absorb after having the noval chemical compound of 39% oral because of gastrointestinal absorption problem.There is absorption problem equally in Chinese medicine.Compared with chemicals, the mechanism of absorption of Chinese medicine or Effective Component of Chinese Medicine is more indefinite.Motherland's Chinese medicine is our rarity, but how Chinese medicine enters blood by the intestines and stomach is the problem that Chinese medicine and pharmacy worker is most interested in, but progress at present in described problem little.
Intestinal permeation enhancers refers to the material that medicine can be promoted at gastrointestinal tract transmembrane transport, and its Main Function mechanism comprises: mobility, the promotion Cell membrane pores of (1) enhancing cell membrane are formed, reduce mucous layer viscosity, improve membrane permeability; (2) suppress hydrolytic enzyme effect, strengthen medicine effect capability development; (3) temporarily change the tight connection between agents area epithelial cell, be beneficial to medicine and pass through; (4) prevent protein aggregation, strengthen the thermodynamic motion of medicine; (5) increase agents area unit interval blood flow, improve the gradient of drug level inside and outside cell membrane.
Current intestinal permeation enhancers mainly contains surfactant-based, cholate, fatty acid and fatty acid salt, bioadhesive high molecular polymer class etc.
Radix Angelicae Sinensis (
angelica sinensis), herbaceos perennial, be distributed in the ground such as Gansu, Yunnan, Sichuan, Qinghai, Shaanxi, Hunan, Hubei, Guizhou in China, all there is cultivation various places.The root of Radix Angelicae Sinensis can be used as medicine, and is one of the most frequently used Chinese medicine.Radix Angelicae Sinensis also can be used in spiced and stewed food batching, and its main feature is flavor and enhancing flavor, increases meat products and medicated incense taste.Radix Angelicae Sinensis can form medicine pair with plurality of Chinese compatibility, but, drug matching and the right Forming Mechanism more complicated of medicine, the concrete mechanism that existing research does not provide Radix Angelicae Sinensis to promote drug absorption and embody rule effect, the indefinite development and application affecting medicine the most at last of mechanism and effect.The conventional Radix Angelicae Sinensis extract adopting the methods such as water extraction, aqueous alkali lifting manipulation, alcohol dipping method, alcohol heat reflux method, alcohol percolation method to prepare, containing volatile oil composition and organic acid, is mainly succinic acid, ligustilide, ferulic acid etc.
Have no Radix Angelicae Sinensis extract at present to report as the technology of related drugs intestinal permeation enhancers.
Summary of the invention
The technical problem to be solved in the present invention is the deficiency overcoming existing natural intestinal absorption enhancer application technology, provides Radix Angelicae Sinensis extract as the application of natural intestinal absorption enhancer.
Object of the present invention is achieved by the following technical programs:
There is provided Radix Angelicae Sinensis extract as the application of the natural intestinal absorption enhancer of medicine.
Described medicine include but not limited to duodenum, jejunum, colon and/or ileum site absorption medicine especially duodenal site absorb medicine.
As one of preferred application scheme, described Radix Angelicae Sinensis extract and compatibility of drugs are applied.
As preferred application scheme two, described Radix Angelicae Sinensis extract and medicine are prepared jointly to be become medicament and applies.
The active component of Radix Angelicae Sinensis extract to a lot of medicine and medicine has significant intestinal absorption facilitation, and more preferably, Radix Angelicae Sinensis extract has significant intestinal absorption facilitation to astragaloside, gastrodine or peoniflorin etc.
Described Radix Angelicae Sinensis extract and medicine are prepared jointly to be become medicament and applies, and preferred dosage form is oral administered dosage form.Include but not limited to as tablet, capsule, granule, oral powder, oral solution, Orally taken emulsion or oral suspensions.
The present invention further provides active component ferulic acid in Radix Angelicae Sinensis extract to apply as the natural intestinal absorption enhancer of medicine.
Preferably, Radix Angelicae Sinensis extract active component ferulic acid significantly can promote that medicine can't cause damage to absorption site in the absorption of duodenal site.
Radix Angelicae Sinensis extract active component ferulic acid significantly can promote that astragaloside is in the absorption of duodenal site.And be realize penetration enhancement effect by improving duodenal absorption rate constant Ka and apparent absorption coefficient Papp.
Beneficial effect of the present invention:
The invention provides the application of Radix Angelicae Sinensis extract as natural intestinal absorption enhancer, described Radix Angelicae Sinensis extract has good intestinal absorption facilitation, and the medicine be promoted enters after in human body, can play cooperative effect, improves the bioavailability of medicine.The application of described Radix Angelicae Sinensis extract, can reduce the dosage of medicine and the use of other intestinal permeation enhancers, reduces the toxic and side effects of medicine and the absorption of other ineffective treatments foreign body.
Research summary of the present invention Radix Angelicae Sinensis extract has significant intestinal absorption facilitation to related drugs, is inquire into the compatibility principle that Radix Angelicae Sinensis and other Chinese medicine forms medicine right to provide strong technical foundation from the angle of intestinal absorption.
Further, the active component ferulic acid that the invention provides Radix Angelicae Sinensis extract is the application of astragaloside intestinal permeation enhancers, ferulic acid has good intestinal absorption facilitation to astragaloside, enter after in human body with astragaloside, cooperative effect can be played, promote that astragaloside is in intestinal absorption effect, improve blood drug level, the toxic and side effects of medicine and the absorption of other ineffective treatments foreign body can be reduced, damage can not be caused to intestinal absorption position mucosa, make full use of ferulic acid, be used as astragaloside intestinal permeation enhancers and there is major application value.
Accompanying drawing explanation
Fig. 1 is that different absorption enhancer is urged to ooze ratio at duodenal Ka to peoniflorin;
Fig. 2 is that absorption enhancer compares at duodenum Papp peoniflorin;
Fig. 3 be ferulic acid astragaloside is absorbed at different intestinal segment impact (
± s, n=5);
Fig. 4 is the promotion of ferulic acid to astragaloside intestinal transport Ka;
Fig. 5 is the promotion of ferulic acid to astragaloside intestinal transport Papp;
Fig. 6 is rat preduodenal intestine colibacillosis (HE dyes, 400 times).
Detailed description of the invention
The present invention is further illustrated below in conjunction with the drawings and specific embodiments.Unless stated otherwise, the raw material adopted in the embodiment of the present invention and method are the conventional commercial raw material in this area and the conventional method used.
Embodiment 1 Radix Angelicae Sinensis extract is tested the intestinal penetration enhancement effect of peoniflorin
The Radix Angelicae Sinensis extract that the present embodiment adopts is purchased from Ze Lang Zhi Ti bio tech ltd, Nanjing; Peoniflorin to come biological engineering company limited purchased from Xi'an, but does not therefore limit the present invention.Those skilled in the art can adopt other Radix Angelicae Sinensis extract of originating and peoniflorins, also can adopt conventional extracting method self-control.
Utilize rat at the unidirectional intestinal perfusion model of body, adopt HPLC method to measure paeoniflorin content in perfusate, investigate Radix Angelicae Sinensis extract respectively to the facilitation of peoniflorin intestinal absorption.
The test of rat at the unidirectional intestinal perfusion model of body is carried out according to following steps method:
S1. Rat Fast 12 h, freely drinks water, 1% Nembutal sodium solution (5 mL/kg) intraperitoneal injection of anesthesia, and back of the body position is fixed, and keeps body temperature;
S2. open abdominal cavity along ventrimeson and be about 3cm, get duodenum about 10 cm, after being in two ends otch apart from pylorus 1 cm, intubate ligation, intestinal contents is rinsed well with 5 mL/min flow velocitys with the normal saline of 37 DEG C of constant temperature, then with air, normal saline is emptying, erecting device;
S3. with the perfusate being preheated to 37 DEG C with 0.2 mL/min flow velocity perfusion 30 minutes, equalizing line and intestinal segment;
S4. start timing, collect 0-15 respectively, the perfusate of 15-30,30-45,45-60,60-75,75-90 min, weighs, record perfusate and collection liquid weight;
S5., at the end of experiment, intestinal segment length and internal diameter is measured.
Measure the content of peoniflorin in perfusate with HPLC method, and be calculated as follows the absorption rate constant Ka and apparent absorption coefficient Papp that calculate medicine:
Wherein, Q
inand Q
outbe respectively the perfusate that intestinal segment pours into and the volume (mL) collecting liquid, l and r is respectively length (cm) and the cross sectional radius (cm) of perfusion intestinal segment, and Q is perfusion rate, C
inand C
outbe respectively perfusate and collect liquid concentration (μ g/mL), V is the volume (cm of perfusion intestinal segment
3).
With the absorption rate constant Ka of medicine and apparent absorption coefficient Papp for index, experimental result shows, HP-β-CD and Radix Angelicae Sinensis extract significantly improve peoniflorin at the absorption rate constant of rat preduodenal and apparent absorption coefficient, show their in the oral formulations of peoniflorin as absorption enhancer use may.
Table 1 absorption enhancer is on the impact of peoniflorin at duodenum Ka
Table 2 absorption enhancer is on the impact of peoniflorin at duodenum Papp
Method same as described above is adopted to test, with absorption rate constant Ka and apparent absorption coefficient Papp for index, the short intestinal absorption effect of Radix Angelicae Sinensis extract to medicines such as astragaloside, gastrodine, peoniflorins is all better than the medicine not adding Radix Angelicae Sinensis extract, and is better than Capric acid sodium salt and the sodium deoxycholate of respective concentration.
Embodiment 2
Laboratory animal: SD rat, male and female half and half, body weight 160 ~ 220 g, Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center provides, the quality certification number: SCXK(Guangdong) 2008-0020.
Instrument: SHIMADZU high performance liquid chromatograph (Japan); TGL-20B high speed centrifuge (Anting Scientific Instrument Factory, Shanghai).
Medicine and reagent: astragaloside reference substance (Nat'l Pharmaceutical & Biological Products Control Institute, lot number: 110781-200613); Acetonitrile, methanol (Di Ma company, chromatographically pure); Water is distilled water.Other reagent are analytical pure.
Krebs-Ringer nutritional solution: hereinafter referred to as K-R liquid, every 1000 ml are containing NaCl 7.8g, KCl 0.35g, NaHCO
31.37g, NaH
2pO
40.32g, MgCl
20.02g, glucose 1.4g, supplies 1000mL with water; Face with preparation, the same day uses.
The present embodiment ferulic acid is purchased from Ze Lang Zhi Ti bio tech ltd, Nanjing (lot number 20110903), but therefore do not limit the present invention, those skilled in the art can adopt other ferulic acids of originating, the ferulic acid that the Radix Angelicae Sinensis extract prepared also can be adopted to carry out separating-purifying obtain.Radix Astragali extract can conventional commercial or self-control (containing astragaloside 13.9%).Homemade method is with reference to the following is: get dry astragalus root raw material, cleaning, dry, 10 times amount 70% ethanol are added, heating and refluxing extraction 2 times, each 3 hours after pulverizing, merge secondary raffinate, decompression recycling ethanol, residue adds suitable quantity of water and dissolves, making containing astragaloside concentration is 0.8 ~ 1.1mg/mL, gets D101 macroporous adsorbent resin, with 2 BV/h loadings, be washed to without Molish reaction, with 5 BV 70% ethanol elutions, collect eluent, decompression recycling ethanol, dry, to obtain final product.
1. everted intestinal sac drug solution preparing
Radix Astragali group: get Radix Astragali extract appropriate, dissolve with Krebs-Ringer nutritional solution and be settled to 100 mL, obtained containing astragaloside 34.75 μ gmL
-1solution.
Compatibility group: by the dosage (the crude drug mass ratio of Radix Angelicae Sinensis and the Radix Astragali is 1:1) of Radix Angelicae Sinensis-Radix Astragali 1:1, with reference to Radix Astragali group concentration, obtains with method.
2. everted intestinal sac experiment
(Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center provides to get healthy SD rat, the quality certification number: SCXK(Guangdong) 2008-0020) overnight fasting (freely drinking water), by 400 mgkg-1 lumbar injection 1% Nembutal sodium solution anesthesia, divide and get different intestinal segment, intestinal is overturn, intestinal capsule Inner injects the blank Krebs-Ringer nutritional solution of 1 mL, this section of intestinal capsule is put in the everted intestinal sac medicinal liquid of preheating, continue to pass into carbon dioxide: the mist of oxygen (5:95) in medicinal liquid, 37 DEG C of insulation 0.5 h.After experiment terminates, collect serosal fluid, measure the content of its Chinese medicine, and measure intestinal absorption area, investigate the absorption of different intestinal segment to astragaloside respectively, and the impact that ferulic acid absorbs astragaloside.
3. the mensuration of everted intestinal sac serosal fluid drug content
Chromatographic column: Diamonsil C18 post (4.6 mm × 250 mm, 5 μm); Mobile phase: acetonitrile-water (32.4:67.6); Column temperature: 25 DEG C; Flow velocity 1.0 mLmL
-1; Sample size: 20 μ L.The specificity of investigation method, result shows, the mensuration of blank intestinal juice to astragaloside is noiseless.Get astragaloside reference substance storing solution appropriate, add the blank intestinal juice of everted intestinal sac, compound concentration is 8.03,16.06,24.06,32.12,40.15,48.18,56.21 μ gmL
-1the solution of series concentration, returns astragaloside concentration (C) peak area (A), obtains standard curve: A=716.8C – 108.53, R=0.9994, the range of linearity: 8.03 ~ 56.21 μ gmL-1.Lowest detectable limit is 1.5 μ gmL
-1.The response rate of high, normal, basic three concentration is 93.9% ~ 97.4%, RSD is 1.40% ~ 2.81%, and withinday precision RSD is 0.54% ~ 0.78%, and day to day precision RSD is 0.58% ~ 0.99%, all meets the requirements.
4. experimental result
Adopt the impact that the rat everted intestinal sac model investigation Radix Astragali absorbs it at absorption and the ferulic acid of different intestinal segment, result shows, astragaloside all has absorption at the whole intestinal segment of small intestinal, different intestinal segment Papp sequence is: duodenum > jejunum > colon > ileum, wherein duodenal absorption is best.After adding ferulic acid, the absorption increase of duodenum and jejunum is comparatively obvious, sees shown in accompanying drawing 3.
5. experiment conclusion
In everted intestinal sac experiment, Zhu Jingyun etc. are active with determination of glucose oxidase intestinal capsule, confirm that in vitro intestinal capsule activity can only maintain 1h, the present invention determines the drug absorption transhipment of time period (0.5h) in everted intestinal sac experiment, and by constant temperature 37 DEG C, pass into oxygen-enriched air, ensure that data are true and reliable.Experimental summary of the present invention finds, ferulic acid can promote the absorption of astragaloside well, especially promotes that astragaloside is in duodenal absorption.
Embodiment 3
1. at body unidirectional intestinal perfusion drug solution preparing
Radix Astragali group: get Radix Astragali extract appropriate, dissolve and be settled to 100 mL with sodium chloride injection, preparation astragaloside concentration is respectively 10.5,15.75,21.00,31.50,36.75 μ gmL
-1the perfusate of totally five gradient concentrations.
Compatibility group: by the dosage (the crude drug mass ratio of Radix Angelicae Sinensis and the Radix Astragali is 1:1) of Radix Angelicae Sinensis-Radix Astragali 1:1, with reference to Radix Astragali group concentration, obtains with method.
2. at the unidirectional intestinal perfusion experiment of body
Get healthy SD rat (Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center provides, the quality certification number: SCXK(Guangdong) 2008-0020) overnight fasting (freely drinking water), by 400 mgkg
-1lumbar injection 1% Nembutal sodium solution is anaesthetized, and opens abdominal cavity, and to investigation intestinal segment (getting about 10 cm) two ends otch intubate, ligation, forms closed circuit.With the normal saline of 37 DEG C, intestinal contents is rinsed well, get 37 DEG C at body unidirectional intestinal perfusion medicinal liquid 100 mL, first with 1.0 mLmin
-1flow velocity perfusion 10 min, then flow velocity is adjusted to 0.2 mLmin
-1, after pre-equilibration 30 min, collect the perfusate of 30 ~ 45,45 ~ 60,60 ~ 75,75 ~ 90,90 ~ 105,105 ~ 120 min time periods and weigh.After experiment terminates, cut intestinal segment, measure absorption area.Measure perfusate concentration, investigate the impact that astragaloside absorbs astragaloside at absorption and the ferulic acid of this intestinal segment respectively.
3. in the mensuration of body intestinal perfusate Chinese medicine
By chromatographic condition under " mensuration of everted intestinal sac serosal fluid drug content " item, the specificity of investigation method, result shows, in intestinal perfusate, impurity does not disturb the mensuration of astragaloside.Get astragaloside reference substance appropriate, be added in the blank intestinal juice of body intestinal perfusion, compound concentration is 8.71,17.42,26.13,34.84,43.55,52.26,60.97 μ gmL
-1the solution of series concentration, centrifugal 10 min of 12000 rpm, get supernatant, with the filtering with microporous membrane of 0.45 μm, get filtrate 20 μ L sample introduction to measure, astragaloside concentration (C) is returned peak area (A), obtains standard curve: A=829.3C-76.24, R=0.9995, the range of linearity: 8.71 ~ 60.97 μ gmL
-1.Lowest detectable limit is 1.7 μ gmL
-1.The response rate of high, normal, basic three concentration is 92.9% ~ 99.3%, RSD is 1.62% ~ 3.53%, and withinday precision 0.64% ~ 1. 86%, day to day precision 0.38% ~ 1.99%, all meets the requirements.
4. the calculating of drug absorption rate constant Ka and medicine apparent absorption coefficient Papp adopts gravimetric method to flow into perfusate and the volume that flows out corrects, eliminate the impact of its change in volume, calculate absorption rate constant Ka and medicine apparent absorption coefficient Papp by following equation:
In above formula: C
inand C
outbe respectively intestinal and import and export perfusate drug level (μ gmL
-1); Q
inand Q
outbe respectively the volume (mL) that intestinal imports and exports perfusate; L and r is respectively perfusion intestinal segment length (cm) and cross sectional radius (cm); For perfusion rate (mLmin
-1); For the volume (cm of perfusion intestinal segment
3).
5. morphocytology inspection
Be taken at the duodenum 1cm before and after body intestinal perfusion experiment respectively, the tissue slice made with HE staining, carries out the morphological examination of epithelium layer, and whether inspection duodenal epithelium cell keeps active upon administration.
6. experimental result
Choose rat preduodenal, adopt at the unidirectional intestinal perfusion model of body, investigate the astragaloside absorbing state of variable concentrations, and investigate the short Absorption of ferulic acid to astragaloside, the results are shown in shown in accompanying drawing 4, accompanying drawing 5, and table 3, shown in table 4.
Table 3 variable concentrations astragaloside compares ER at the absorption water molecules Ka of rat preduodenal with short oozing
Note: compared with Radix Astragali group, compatibility group all has significant difference, * P<0.05.
Table 4 variable concentrations astragaloside compares ER at the apparent permeability coefficients Papp of rat preduodenal with short oozing
Result shows, the astragaloside of variable concentrations has absorption at duodenum, and after adding ferulic acid, Ka and Papp all increases.
7 morphocytology inspections
Intestinal villi after administration is substantially complete, without obviously damaging, compared with before administration, being substantially consistent, seeing shown in accompanying drawing 6.Prove that the compatibility of astragaloside and ferulic acid of the present invention and astragaloside uses not damage intestinal segment, experimental session intestinal keeps absorbing activity.
8. experiment conclusion
In the unidirectional intestinal perfusion experiment of body, the Radix Astragali, in duodenal absorption, shows as and raises with concentration and increase, show the feature of Passive intake under middle low concentration; But at higher concentrations, Ka and Papp reduces all to some extent, point out the possibility that the intestinal transport of astragaloside has carrier to participate in.
Under the effect of ferulic acid, Ka and the Papp of astragaloside increases all to some extent, and ER value is all greater than 1, and there is significant difference (P<0.05); Wherein with middle concentration (21.00 μ gmL
-1) short assimilation effect the most obvious: ERKa=1.42, ERPapp=1.47, it is relevant with astragaloside concentration that the display intestinal of ferulic acid to the Radix Astragali urgees absorbability.
Claims (8)
1. the Radix Angelicae Sinensis extract containing ferulic acid is preparing as the natural intestinal absorption enhancer of medicine astragaloside, gastrodine or peoniflorin the application had in the pharmaceutical preparation of the intestinal absorption of improvement.
2. application according to claim 1, it is characterized in that, the described Radix Angelicae Sinensis extract containing ferulic acid is preparing as the absorption enhancer at the duodenum of medicine astragaloside, gastrodine or peoniflorin, jejunum, colon or ileum one of them or several position the application had in the pharmaceutical preparation of the intestinal absorption of improvement.
3. application according to claim 2, it is characterized in that, the described Radix Angelicae Sinensis extract containing ferulic acid is preparing as the duodenal absorption enhancer of medicine astragaloside, gastrodine or peoniflorin the application had in the pharmaceutical preparation of the intestinal absorption of improvement.
4. application according to claim 1, is characterized in that, the described Radix Angelicae Sinensis extract containing ferulic acid and compatibility of drugs are applied.
5. application according to claim 1, is characterized in that, described Radix Angelicae Sinensis extract containing ferulic acid and medicine are prepared jointly to be become medicament and apply.
6. application according to claim 5, is characterized in that, described medicament is oral administered dosage form.
7. application according to claim 6, is characterized in that, described oral administered dosage form is tablet, capsule, granule, oral powder, oral solution, Orally taken emulsion or oral suspensions.
8. application according to claim 1, is characterized in that, described medicine is astragaloside.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410017214.XA CN103751792B (en) | 2014-01-15 | 2014-01-15 | Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410017214.XA CN103751792B (en) | 2014-01-15 | 2014-01-15 | Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103751792A CN103751792A (en) | 2014-04-30 |
| CN103751792B true CN103751792B (en) | 2015-10-28 |
Family
ID=50519213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410017214.XA Expired - Fee Related CN103751792B (en) | 2014-01-15 | 2014-01-15 | Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751792B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112899217A (en) * | 2021-01-29 | 2021-06-04 | 江西中医药大学 | Medicated liver incubation liquid pharmacologic method and preparation method of medicated liver incubation liquid of ephedra, apricot kernel, gypsum and licorice decoction |
| CN112957415A (en) * | 2021-02-23 | 2021-06-15 | 成都西域从容生物科技有限公司 | NMN composition beneficial to intestinal absorption and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007012A (en) * | 2006-01-23 | 2007-08-01 | 天津药物研究院 | An oral mucosal absorbent preparation containing active components of astragaloside IV |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013184939A (en) * | 2012-03-08 | 2013-09-19 | Kobe Gakuin | Body weight increase inhibitor |
-
2014
- 2014-01-15 CN CN201410017214.XA patent/CN103751792B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007012A (en) * | 2006-01-23 | 2007-08-01 | 天津药物研究院 | An oral mucosal absorbent preparation containing active components of astragaloside IV |
Non-Patent Citations (2)
| Title |
|---|
| "当归-川芎"药对中阿魏酸在体肠吸收研究;白晶 等;《哈尔滨商业大学学报(自然科学版)》;20130430;第29卷(第2期);129-132页 * |
| 川芎提取物中阿魏酸大鼠在体肠吸收动力学的研究;杨星钢 等;《中草药》;20070131;第38卷(第1期);61-64页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103751792A (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103319479B (en) | Rhubarb yellow berberine ion-pair compound, preparation method and application | |
| CN101919961B (en) | Drug composition for treating cold and preparation method thereof | |
| CN100457139C (en) | Method for preparing a Shuanhuanglian injection and the component detecting method | |
| CN103610757B (en) | For the parenteral solution of clearing heat and eliminating phlegm removing toxic substances | |
| CN104435226B (en) | Fevervine extract and application thereof | |
| CN101274025A (en) | Chinese medicinal composition with functions of reducing fever, purging the intense heat and detoxicating and preparation method thereof and quality control method | |
| CN103316096A (en) | General flavone extract of seeds of nigella damascena l., nigella sativa l. or nigella glandulifera freyn et sint., and preparation method and use thereof | |
| CN103751792B (en) | Radix Angelicae Sinensis extract is as the application of natural intestinal absorption enhancer | |
| CN105338993A (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
| CN106617079A (en) | Purpose of ganoderan in preparation of health food for regulating flora in intestinal tract | |
| CN1883566B (en) | Anti-inflammation medicine and method for preparing same | |
| CN104367987A (en) | Astragalus mongholicus formulation for veterinary use and preparation method thereof | |
| CN1879688B (en) | Preparation for treating wind-heat type cold, its preparation process and quality control method | |
| CN105327071A (en) | Antineoplastic traditional Chinese medicinal composition and application thereof | |
| CN103191424A (en) | Astragalus polysaccharide nanoliposome capable of improving livestock and poultry immunity and preparation method thereof | |
| CN102274264B (en) | Application of platycodon root total saponin in medicaments for treating and preventing mycoplasma pneumoniae infectious diseases | |
| CN102475749B (en) | Traditional Chinese medicine transdermal agent for treating dairy cow recessive mastitis and preparation method of transdermal agent | |
| CN101933996A (en) | Chinese medicinal composition having effects of clearing heat, relieving fire and eliminating toxins and preparation and detection methods thereof | |
| CN1733125B (en) | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark | |
| CN1947749B (en) | Medicine composition containing Poria cocos and Touhualiao (polygonaceae) | |
| Deng et al. | Amelioration of muscular spasm-induced pain of Guangtongxiao recipe in a non-everted gut sac in vitro model | |
| CN103181891A (en) | Andrographolide injection and preparation method thereof | |
| CN104383547B (en) | Herba Saussureae Involueratae extract phosphatide complexes, oral disnitegration tablet and preparation method thereof | |
| CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
| CN101468133A (en) | Pharmaceutical composition for treating inflammation of gynecology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 510006 Guangdong City, Guangzhou province outside the University of East Ring Road, No. 280 Applicant after: Guangdong Pharmaceutical University Address before: 510224 Haizhuqu District City, Guangzhou Province Po Po Kong Han straight street, No. 40 Applicant before: Guangdong Pharmaceutical University |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 510240 40 Haizhuqu District, Guangdong, Guangzhou. Patentee after: GUANGDONG PHARMACEUTICAL University Address before: 510006 No. 280 East Ring Road, Guangzhou City University, Guangdong Patentee before: Guangdong Pharmaceutical University |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 |